Elicio Therapeutics, Inc.
ELTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeElicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. With a market capitalization of $51.5M, it sits in micro-cap territory. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Market Cap
$51.5M
Beta
1.98
P/E (TTM)
—
P/E (Fwd)
-1.12
EPS (TTM)
$-2.16
EPS (Fwd)
$-1.69
ROE
-774.6%
ROA
-77.9%
Cash
$23.5M
Total Debt
$14.1M
Free CF
-$22.3M
52W Change
-80.4%
Annual Financials
Cash vs Debt
Where ELTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ELTX finished 75.40% below its 150-day moving average ($6.30) and 78.05% below its 200-day moving average ($7.06). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ELTX overbought or oversold?
At the October 20, 2026 close, ELTX's RSI(14) was 29.0, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Elicio Therapeutics, Inc. holds $23.5M in cash against $14.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$22.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -774.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 1.98 means ELTX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Elicio Therapeutics, Inc.'s trajectory.